A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of IPI-145 in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Phase of Trial: Phase III
Latest Information Update: 08 Jan 2019
Price : $35 *
At a glance
- Drugs Duvelisib (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms DYNAMO+R
- Sponsors Infinity Pharmaceuticals; Verastem Oncology
- 03 May 2018 According to a Verastem Oncology media release, Verastem changed its name to Verastem Oncology.
- 13 Apr 2017 This trial has been completed in Denmark (End date:2017-03-03) and discontinued in Belgium, according to European Clinical Trials Database.
- 10 Apr 2017 Status changed from active, no longer recruiting to discontinued.